Scinai Immunotherapeutics Reports Improved Financials and Strengthened Cash Position in First-Half 2025 Results
TL;DR
Scinai Immunotherapeutics reduced its net loss and raised $4.2 million, strengthening liquidity and positioning for growth in its CDMO and NanoAb programs.
Scinai's revenues grew to $773,000 with R&D expenses falling to $1.24 million, while securing patents and pursuing €27 million in grant funding.
Scinai's anti-IL-17 NanoAb program and CDMO services advance treatments for inflammation and immunology diseases with large unmet medical needs.
Scinai filed new patents under its Max Planck collaboration and booked $1.0 million in CDMO service orders through August 2025.
Found this article helpful?
Share it with your network and spread the knowledge!
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, representing substantial growth from $284,000 in the prior-year period. This performance reflects continued expansion in the company's contract development and manufacturing organization (CDMO) business unit, which has booked $1.0 million in service orders through August 2025.
The company's research and development expenses decreased significantly to $1.24 million from $2.79 million in the comparable period, while marketing, general and administrative expenses increased to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier, indicating improved operational efficiency and cost management.
Scinai's cash position strengthened considerably, with cash and equivalents totaling $989,000 as of June 30, 2025. The company further enhanced its liquidity by raising an additional $4.2 million in July and August under its Standby Equity Purchase Agreement. This financial stability is crucial for advancing the company's pipeline development and supporting ongoing operations.
The company made significant progress in its anti-IL-17 NanoAb program, filing new patents under its collaboration with Max Planck. Scinai is actively pursuing up to €27 million in grant funding to support clinical trials and pipeline development activities. These developments are important for investors and the biotechnology sector as they demonstrate Scinai's ability to advance innovative therapeutic programs while maintaining financial discipline.
The company's progress in both its therapeutic development and CDMO businesses positions it well within the competitive biopharmaceutical landscape. For more detailed financial information and corporate updates, investors can access the company's newsroom at https://ibn.fm/SCNI. The full press release containing these results is available at https://ibn.fm/cJ0J7.
Curated from InvestorBrandNetwork (IBN)
